The South West Area Mesothelioma and Pemetrexed trial - A multi-centre prospective observational study evaluating novel markers of chemotherapy response and prognostication

Lowndes, S. A.; White, P.; Hooper, C. E.; Lyburn, I. D.; Searle, J.; Darby, M.; Hall, T.; Hall, D.; Morley, A.; White, Paul; Rahman, N. M.; De Winton, E.; Clive, A.; Masani, V.; Arnold, D. T.; Dangoor, A.; Guglani, S.; Jankowska, P.; Lowndes, P; Harvey, J. E.; Braybrooke, J. P.; Maskell, N. A.

doi:10.1038/bjc.2015.62

The South West Area Mesothelioma and Pemetrexed trial - A multi-centre prospective observational study evaluating novel markers of chemotherapy response and prognostication

Lowndes, S. A.; White, P.; Hooper, C. E.; Lyburn, I. D.; Searle, J.; Darby, M.; Hall, T.; Hall, D.; Morley, A.; White, Paul; Rahman, N. M.; De Winton, E.; Clive, A.; Masani, V.; Arnold, D. T.; Dangoor, A.; Guglani, S.; Jankowska, P.; Lowndes, P; Harvey, J. E.; Braybrooke, J. P.; Maskell, N. A.

Authors

S. A. Lowndes

P. White

C. E. Hooper

I. D. Lyburn

J. Searle

M. Darby

T. Hall

D. Hall

A. Morley

Paul White Paul.White@uwe.ac.uk
Professor in Applied Statistics

N. M. Rahman

E. De Winton

A. Clive

V. Masani

D. T. Arnold

A. Dangoor

S. Guglani

P. Jankowska

P Lowndes

J. E. Harvey

J. P. Braybrooke

N. A. Maskell

Abstract

© 2015 Cancer Research UK. All rights reserved. Background: Robust markers that predict prognosis and detect early treatment response in malignant pleural mesothelioma (MPM) would enhance patient care. Methods: Consecutive patients with MPM who were considered fit for first-line chemotherapy were prospectively recruited. Patients of similar performance status opting for best supportive care were included as a comparator group. Baseline and interval CT, PET-CT and serum markers (mesothelin, fibulin-3 and neutrophil-lymphocyte ratio (NLR)) were obtained, and patients followed up for a minimum 12 months. Findings: Seventy-three patients were recruited (58 chemotherapy/15 comparator arm). Baseline TGV (total glycolytic volume on PET-CT) was an independent predictor of worse overall survival (OS) (P=0.001). Change in interval TGV(baseline/after two cycles of chemotherapy) did not predict OS or chemotherapy response on CT. Baseline NLR

Citation

Lowndes, S. A., White, P., Hooper, C. E., Lyburn, I. D., Searle, J., Darby, M., …Maskell, N. A. (2015). The South West Area Mesothelioma and Pemetrexed trial: A multicentre prospective observational study evaluating novel markers of chemotherapy response and prognostication. British Journal of Cancer, 112(7), 1175-1182. https://doi.org/10.1038/bjc.2015.62

Journal Article Type	Article
Publication Date	Jan 1, 2015
Journal	British Journal of Cancer
Print ISSN	0007-0920
Publisher	Springer Nature [academic journals on nature.com]
Peer Reviewed	Peer Reviewed
Volume	112
Issue	7
Pages	1175-1182
DOI	https://doi.org/10.1038/bjc.2015.62
Keywords	chemotherapy, response and prognostication, SWAMP, observational study
Public URL	https://uwe-repository.worktribe.com/output/842472
Publisher URL	http://dx.doi.org/10.1038/bjc.2015.62
Related Public URLs	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4385956/pdf/bjc201562a.pdf